EU Notified Body Timelines: New MDR & IVDR Rules for Predictable CE Marking

South Korea Medical Device Act 2026: MFDS QMS and Distribution Rule Changes

This episode details the significant amendments to South Korea's Medical Device Act, effective July 1, 2026. We cover the two key changes from the Ministry of Food and Drug Safety (MFDS): the formalization of the Quality Management System (QMS) Conformity Recognition Scheme and the new mandatory supply chain record-keeping rules. We explore the impact on manufacturers, importers, and distributors and provide actionable steps for regulatory and quality teams to ensure compliance with these new traceability and oversight requirements. Key Questions: - What are the key changes in South Korea's amended Medical Device Act effective July 1, 2026? - How does the formalization of the QMS Conformity Recognition Scheme impact MFDS audits? - What new traceability and record-keeping requirements are being imposed on the medical device supply chain? - Who is responsible for maintaining distribution records under the new MFDS rules? - How does this amendment affect manufacturers, importers, distributors, and sellers in South Korea? - Can participation in programs like MDSAP simplify compliance with the new QMS requirements? - What practical steps should my regulatory team take now to prepare for the 2026 deadline? - How will these changes enhance patient safety and post-market surveillance in South Korea? Sources: - https://www.regdesk.co/south-korea-mfds-2026-medical-device-act-amendments-qms-conformity-recognition/ - https://www.youtube.com/watch?v=YOUR_VIDEO_ID_FOR_RESULT_16 How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, simplifying global market access. We act as your local representative in over 30 markets, including South Korea, and develop efficient regulatory strategies to get your products approved faster. Our AI-powered platform streamlines the creation and management of technical dossiers for MFDS submissions. We help you navigate complex requirements like the new distribution rules and ensure your QMS aligns with local expectations. Visit https://pureglobal.com or contact us at info@pureglobal.com. Explore our free AI tools and device database at https://pureglobal.ai.

Saudi Arabia SFDA Risk Communication Guidance: What MDS-G-029 Means for Manufacturers

The Saudi Food and Drug Authority (SFDA) published a new guidance, MDS-G-029, on July 9, 2026, establishing formal requirements for medical device risk communication. This episode breaks down the key principles of the guidance, including the responsibilities of manufacturers and their Authorized Representatives, the expected content and channels for communication, and the impact on post-market surveillance and vigilance systems for devices sold in Saudi Arabia. Key Questions: - What is the new SFDA guidance MDS-G-029 about? - Who does this new risk communication requirement apply to? - What are the key principles for communicating medical device risks in Saudi Arabia? - What specific information must be included in a risk communication notice? - How does this guidance impact manufacturers' post-market surveillance obligations? - What is the role of the Authorized Representative in this process? - What are the different types of communication channels the SFDA expects? - What practical steps should my team take now to prepare for compliance? Sources: - https://www.sfda.gov.sa/sites/default/files/2026-07/MDS-G-029-V1.pdf - https://www.sfda.gov.sa/en/medicaldevices How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, including Saudi Arabia, and our experts can help you align your post-market surveillance and vigilance systems with new requirements like the SFDA's MDS-G-029. Our AI-powered tools accelerate the creation of technical documentation and help you monitor regulatory changes, ensuring continuous compliance. Whether you need to develop a regulatory strategy, manage submissions, or maintain your market presence, we offer a single, efficient process for multiple markets. Contact us at info@pureglobal.com or visit https://pureglobal.com to learn more and access our free regulatory AI tools and database at https://pureglobal.ai.

Health Canada Ministerial Reliance Order: Faster Market Access for Medical Devices

Health Canada has introduced a new Ministerial Reliance Order, effective July 15, 2026, designed to accelerate market access for medical devices and drugs. This episode breaks down how the new reliance pathway allows manufacturers to leverage approvals from trusted foreign regulators to expedite the Canadian review process. We discuss the potential eligibility criteria, the critical public consultation period ending on September 12, 2026, and provide practical, actionable steps for regulatory and quality teams to prepare their submission strategies. Key Questions: - What is Health Canada's new Ministerial Reliance Order? - How does this order accelerate the review process for medical devices? - Which foreign regulatory approvals will Health Canada likely recognize? - What are the potential eligibility criteria for devices under this new pathway? - Why is the September 12, 2026, deadline for public consultation so important? - How can manufacturers prepare their submissions to leverage this reliance route? - What documentation is needed to demonstrate equivalence with a foreign approval? - What are the immediate implications of this order for your Canadian market access strategy? - Should you re-prioritize Canada in your global launch sequence? Sources: - https://www.canada.ca/en/health-canada/news/2026/07/helping-canadians-access-safe-effective-treatments-and-medicines-faster.html How Pure Global can help: Navigating new regulatory pathways like Health Canada's Ministerial Reliance Order requires local expertise and a clear strategy. Pure Global provides end-to-end support for MedTech and IVD companies, acting as your local representative and developing efficient pathways for regulatory approval in Canada and over 30 other markets. Our experts use advanced AI to compile and manage technical dossiers, ensuring your submissions are optimized for accelerated review. Let us help you leverage your existing approvals to access the Canadian market faster. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and database at https://pureglobal.ai.

UK MHRA Draft Medical Device Regulations 2026: Key Changes and Timeline

This episode covers the closing of the WTO comment period on July 7, 2026, for the UK MHRA's draft Medical Devices (Amendment) Regulations 2026. We break down the key changes manufacturers need to prepare for, including the new international reliance pathway for approvals from other major regulators, the implementation of a UK-specific Unique Device Identification (UDI) system, and the significant shift to a risk-based classification system for In-Vitro Diagnostics (IVDs). We also discuss the expected timeline for these regulations to become law in late 2026 and provide practical steps for regulatory and quality teams to begin their transition planning. Key Questions: - What does the closing of the WTO comment period on July 7, 2026, mean for the UK's new medical device rules? - How will the proposed international reliance pathway change market access strategy for Great Britain? - What are the key details of the UK's planned Unique Device Identification (UDI) system? - How will In-Vitro Diagnostic (IVD) devices be reclassified under the new risk-based framework? - What is the expected timeline for the 2026 regulations to become law? - What steps should regulatory teams take now to prepare for these significant changes? - How do the new rules affect software as a medical device (SaMD) and implantable devices? Sources: - https://www.dacbeachcroft.com/en/gb/articles/2026/june/mhra-publishes-draft-regulations-for-medical-device-reform/ - https://www.gov.uk/government/news/mhra-invites-views-on-proposed-changes-to-medical-device-regulation - https://www.pinsentmasons.com/out-law/news/mhra-publishes-draft-2026-medical-device-regulations-for-gb-market - https://www.linkedin.com/pulse/mhra-publishes-draft-amendment-uk-medical-devices-regulations-dpcnf How Pure Global can help: Pure Global offers end-to-end regulatory consulting to help MedTech and IVD companies navigate complex market transitions like the UK's new 2026 regulations. Our experts develop efficient regulatory strategies, leveraging new pathways like international reliance to accelerate your market access. We act as your local UK Responsible Person, manage technical dossier compilation using advanced AI, and provide continuous regulatory monitoring to ensure ongoing compliance. Whether you're a startup or a multinational, we streamline your path to the UK market. Contact us at info@pureglobal.com, visit https://pureglobal.com, or explore our free AI tools and regulatory database at https://pureglobal.ai to get started.

EU REP Symbol Transition: Compliance Guide for Medical Device Labeling by 2031

This episode details the formal transition from the 'EC REP' to the 'EU REP' symbol for European Authorized Representatives on medical device and IVD labeling. We discuss the implications of the amended harmonized standard EN ISO 15223-1:2021/A1:2025, published on June 17, 2026. The host explains the 60-month transition period, which ends on June 17, 2031, and provides practical, actionable steps for manufacturers to update their technical documentation, QMS, labeling, and packaging to ensure continued compliance in the European Union. Key Questions: - What is the significance of the EU REP symbol change? - When is the official deadline to stop using the EC REP symbol? - Does this change affect both medical devices and IVDs? - What specific standard was updated to formalize this transition? - How long is the transition period for implementing the new EU REP symbol? - What are the first steps a manufacturer should take to manage this change? - How does this labeling update impact technical documentation and the QMS? - Should manufacturers coordinate this change with their Notified Body? - Can both the EC REP and EU REP symbols be used simultaneously during the transition? - What is a practical strategy for updating packaging and labeling across a large product portfolio? Sources: - https://www.medqair.com/medical-device-regulatory-news/ec-rep-to-eu-rep-what-the-ojeu-publication-means-in-practice - https://www.decomplix.com/regulatory-news/ - https://www.pure-global.com/regulatory-updates How Pure Global can help: Pure Global provides end-to-end regulatory consulting for MedTech and IVD companies, streamlining global market access. We act as your local representative in over 30 markets, develop efficient regulatory strategies, and use advanced AI to compile and manage technical dossiers for submission. Our team of local experts helps you navigate complex requirements like labeling changes to ensure your products remain compliant and reach markets faster. For support with your EU regulatory strategy and technical file updates, contact us at info@pureglobal.com or visit https://pureglobal.com. Explore our free AI tools and regulatory database at https://pureglobal.ai.